Category Archives: Neurology

Tysabri (natalizumab) Drug Safety Communication

Posted on January 23, 2012 by Ws Revelations

Tysabri (natalizumab): Drug Safety Communication – New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML) AUDIENCE: Neurology, Gastroenterology ISSUE: FDA notified healthcare profesisonals that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal … Continue reading →

Posted in FDA 2012, FDA Notice, Gastroenterology, Neurology | Tagged , , , , , , , , | Comments Off

Adcetris (brentuximab vedotin) Drug Safety Communication

Posted on January 13, 2012 by Ws Revelations

Adcetris (brentuximab vedotin): Drug Safety Communication – Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity AUDIENCE: Oncology, Hematology, Neurology ISSUE: FDA notified healthcare professionals that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in … Continue reading →

Posted in FDA 2011, FDA Label Change, FDA Notice, FDA Warning, Hematology, Neurology, Oncology | Tagged , , , , , , , , , | Comments Off

Gilenya (fingolimod) Drug Safety Communication

Posted on December 28, 2011 by Ws Revelations

Gilenya (fingolimod): Drug Safety Communication – Safety Review of a Reported Death After the First Dose AUDIENCE: Neurology, Patients ISSUE: The FDA has received a report of a patient with multiple sclerosis (MS) who died within 24 hours of taking … Continue reading →

Posted in FDA 2011, FDA Notice, multiple sclerosis (MS), Neurology | Tagged , , , , , | Comments Off